Sermorelin Peptide: Status, Evidence and Sellers

Sermorelin reproduces the first 29 amino acids of human growth-hormone-releasing hormone. Instead of supplying growth hormone from outside, it tells the pituitary to make and release your own. That leaves the hypothalamic-pituitary feedback loop that normally restrains the system fully intact.

It was once sold as Geref, approved for diagnosing and treating growth hormone deficiency in children [1]. The manufacturer discontinued it in 2008, and FDA later determined that it was not withdrawn for reasons of safety or effectiveness. What exists now is compounded: dispensed by licensed pharmacies on a prescription, with no branded product behind it.

Adult-wellness practitioners have taken an interest in it for supporting the GH axis as it declines with age, sometimes called somatopause. The evidence is far stronger for the childhood indication than for that use, and no large, long-term, placebo-controlled trial in healthy older adults has ever been published. Keep that gap in mind when reading any marketing about it.

It binds GHRH receptors on the somatotroph cells of the anterior pituitary, switches on cAMP signaling, and prompts growth hormone to be made and released in pulses. Because somatostatin still inhibits the pituitary normally, feedback control over GH stays in place, and that is the physiologic difference from injecting growth hormone directly [6]. Its half-life after a subcutaneous injection is short, around 10 to 12 minutes, so the stimulation it produces is a pulse rather than a plateau.

The GH released then drives the liver to produce IGF-1, and IGF-1 mediates most of the tissue-building, fat-releasing and repair effects attributed to growth hormone. Since the whole chain starts at the pituitary, anyone whose pituitary is significantly damaged (after radiation, for instance) may respond weakly or not at all [5].

The clearest evidence is in children with growth hormone deficiency. A multicenter trial found that once-daily subcutaneous GHRH(1-29) significantly accelerated growth velocity through the first year of treatment [2]. A separate study reported sustained increases in growth velocity in children with idiopathic short stature [3]. One comprehensive literature review concluded it worked as an alternative to recombinant growth hormone for idiopathic childhood deficiency, with comparable tolerability [1].

In adults the picture is thinner and leans on inference. In older men and women, a controlled study of a closely related analog found GH secretion enhanced and body composition trending favorably against baseline, though the trial was small and the analog was not identical to standard sermorelin, which limits how far the result travels [4]. Another study reported GHRH treatment partially restoring GH secretion where radiation therapy had damaged the axis [7].

A further study found the GH response to low-dose GHRH(1-29) markedly blunted in patients with longstanding post-irradiation insufficiency, which reinforces the central limitation: some pituitary reserve has to remain for any of this to work [5]. The claims that sell it concern lean mass, fat mass, sleep and libido in healthy aging adults, and not one randomized human trial has ever made any of them its primary focus. Those claims are extrapolations from what growth hormone does, not findings about this peptide.

No sermorelin product is approved today. Geref, the branded version, was approved for diagnostic use and later discontinued, so no current label sets a dose. The published doses come from older studies. A 1996 trial in children with growth hormone deficiency gave 30 mcg per kg under the skin once daily and found faster growth [2]. A 1997 study in men and women aged 55 to 71 used a closely related GHRH analog at 10 mcg per kg each night for 16 weeks and recorded higher overnight GH and IGF-1 [4].

Neither study tested the adult anti-aging and body-composition uses sermorelin is sold for today, and the schedules compounding prescribers use are not taken from a trial. This page does not repeat them. Where it is prescribed, IGF-1 is the measure that shows whether anything biological is happening.

Being compounded, it falls outside the manufacturing oversight that applies to approved drug products, so sterility, potency and purity vary between pharmacies. Reported side effects are mostly minor and local: redness or swelling where injected, flushing, headache [1]. And because everything depends on the pituitary responding, it will not raise GH at all in someone with significant hypopituitary damage.

Keeping somatostatin feedback intact should in theory limit the risk of pathological GH excess compared with injecting growth hormone, but that theoretical advantage has never been tested head to head in a controlled trial. It is generally avoided in anyone with active or previous malignancy, since the GH and IGF-1 axis promotes growth. Anyone otherwise healthy who takes it is taking it off-label.